Proposal for individualized dosing of eculizumab in atypical haemolytic uraemic syndrome: patient friendly and cost-effective

BACKGROUND: Eculizumab is a lifesaving yet expensive drug for atypical haemolytic uraemic syndrome (aHUS). Current guidelines advise a fixed-dosing schedule, which can be suboptimal and inflexible in the individual patient. METHODS: We evaluated the pharmacokinetics (PK) and pharmacodynamics (PD) [c...

Descripción completa

Detalles Bibliográficos
Autores principales: ter Avest, Mendy, Bouwmeester, Romy N, Duineveld, Caroline, Wijnsma, Kioa L, Volokhina, Elena B, van den Heuvel, Lambertus P W J, Burger, David M, Wetzels, Jack F M, van de Kar, Nicole C A J, ter Heine, Rob
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9923710/
https://www.ncbi.nlm.nih.gov/pubmed/35238929
http://dx.doi.org/10.1093/ndt/gfac056

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9923710/
https://www.ncbi.nlm.nih.gov/pubmed/35238929
http://dx.doi.org/10.1093/ndt/gfac056

Ejemplares similares